港股異動|雲頂新耀升超4% 與Kezar簽訂合作協議引進創新藥
雲頂新耀快速拉昇,升4.3%,報18.92港元。雲頂新耀與生物製藥公司Kezar訂立合作及授權許可協議。雲頂新耀獲獨家授權許可在大中華區、韓國及若干東南亞國家開發、生產及商業化Kezar的主要候選藥物Zetomipzomib。公司稱,Zetomipzomib是一款用於治療包括狼瘡性腎炎在內的一系列自身免疫性疾病的候選藥物,而腎科和自身免疫性疾病是公司的戰略聚焦重點,與公司的業務佈局非常契合。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.